Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Teva “Authorized” Generic Agreement Approved By FTC

This article was originally published in The Pink Sheet Daily

Executive Summary

A settlement allowing Teva to launch generic carboplatin in June is not anti-competitive, the Federal Trade Commission says. The agreement encourages price competition and gives Teva an incentive to launch under an ANDA as soon as possible, FTC says.
Advertisement

Related Content

“Authorized” Generics Fight Moves To Capitol Hill, FTC
“Authorized” Generics Fight Moves To Capitol Hill, FTC
Corixa Names Marketing VP
Corixa Names Marketing VP
Paraplatin "Authorized" Generic To Be Launched By Teva
Paraplatin "Authorized" Generic To Be Launched By Teva
"Authorized" Generics Reduce The Incentive For Patent Challenges, GPhA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS059511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel